Modified systemic immune-inflammatory index, modified systemic inflammatory response index and hemoglobin-albumin-lymphocyte-platelet score may serve as markers for evaluating the efficacy of neoadjuvant therapy in breast cancer patients
{{output}}
Objective: To explore the evaluation value of the modified systemic immune-inflammatory index (mSII), modified systemic inflammatory response index (mSIRI) and hemoglobin-albumin-lymphocyte-platelet (HALP) score for the efficacy ... ...
